葡萄糖受体家族的脂质调节
Affiong Ika Oqua1, Yusman Manchanda1, Emma Rose McGlone2
1Section of Cell Biology and Functional Genomics, Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.
The Journal of endocrinology
|April 13, 2024
概括
脂质,特别是胆固醇,因其在调节葡萄糖受体家族 (GPCRs) 中的作用而越来越被认可. 本综述探讨了脂质如何影响葡萄糖受体信号传递和贩运,为代谢调节提供了新的见解.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 代谢过程中的代谢.
背景情况:
- 葡萄糖受体家族是B1类G蛋白合受体 (GPCRs),对代谢控制至关重要.
- GPCR与脂质二层相互作用,表明脂质可以调节它们的功能.
- 受体和激动剂的脂质修饰可以改变结合和信号传递.
研究的目的:
- 要总结当前对胆固醇对葡萄糖受体家族信号传递和贩运的影响的知识.
- 审查直接的脂质受体相互作用和通过激动剂修饰的间接影响的证据.
- 在此背景下讨论研究脂质受体相互作用的方法.
主要方法:
- 关于脂质-GPCR相互作用的现有研究的文献综述.
- 对葡萄糖受体家族胆固醇调节数据的分析.
- 讨论研究脂质受体结合和影响的技术.
主要成果:
- 新出现的证据表明脂质,特别是胆固醇,影响葡萄糖受体家族的信号传递和贩运.
- 通过激动性脂质修饰观察到特定的脂质受体结合和间接效应.
- 研究这些相互作用的方法正在开发和完善.
结论:
- 脂质相互作用是葡萄糖受体家族生物学中的重要,但尚未研究的因素.
- 了解这些相互作用对于理解新陈代谢调节至关重要.
- 对脂质受体动态的进一步研究将增强我们对这些代谢相关受体的了解.
相关概念视频
Glucagon-like Receptor Agonists
319
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
319
Insulin: The Receptor and Signaling Pathways
1.2K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.2K
GPCRs Regulate Adenylyl Cylase Activity
5.5K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.5K
Hormones Regulating Blood Glucose
3.3K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.3K
Glucose Homeostasis: Regulation of Blood Glucose
1.6K
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
1.6K
Hypoglycemia and Glucagon
257
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
257


